12
ALL1
Perrigo Company plc1
Prague Scientific10
RedHill BiopharmaYear
12
ALL3
20234
20222
20213
2020DEALS // DEV.
12
ALL5
Deals7
DevelopmentsCountry
12
ALL1
CZECH REPUBLIC1
IRELAND10
ISRAEL12
ALL1
Cosmo Pharmaceuticals1
Entera Health1
Gaelan Medical1
HealthCare Royalty Partners7
Not Applicable1
PhilTherapeutic Area
12
ALL2
Gastroenterology10
Infections and Infectious DiseasesStudy Phase
12
ALL12
ApprovedDeal Type
5
ALL1
Agreement1
Financing2
Licensing Agreement1
TerminationProduct Type
12
ALL12
Small moleculeDosage Form
12
ALL8
Capsule3
Capsule, Delayed Release1
Immediate Release CapsuleLead Product
12
ALL12
Omeprazole MagnesiumTarget
8
ALL8
Potassium-transporting ATPaseLead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RedHill Announces FDA sNDA Approval for Talicia®
Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2023
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics and a proton pump inhibitor (PPI) (omeprazole), used for the treatment of H. pylori infection.
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2023
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Phil
Deal Size : Undisclosed
Deal Type : Agreement
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
Details : Under the agreement, RedHill will make Talicia, a novel, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole magnesium), approved for H. pylori infection, available via the PhilRx Pat...
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Phil
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...
Brand Name : Omeprazole Magnesium-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 25, 2022
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Perrigo Announces U.S. FDA Approval For Omeprazole Magnesium Delayed-Release Mini Capsules
Details : Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.
Brand Name : Omeprazole Magnesium-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 26, 2022
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RedHill Presents New Talicia® Data Analyses at DDW 2022
Details : Talicia (Omeprazole Magnesium) efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradicati...
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2022
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Gaelan Medical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Gaelan Medical will receive the exclusive rights to commercialize Talicia in the UAE, as well as a right of rst refusal to [1] 1 commercialize Talicia in the Gulf Cooperation Council region (Saudi Arabia, Kuwait, Qatar, Bahrain and Oman) for a pre-determ...
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : $2.0 million
January 06, 2022
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Gaelan Medical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
Details : Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnes...
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2021
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnes...
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2021
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Cosmo Pharmaceuticals
Deal Size : $21.0 million
Deal Type : Licensing Agreement
RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership
Details : Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug.
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 13, 2020
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Cosmo Pharmaceuticals
Deal Size : $21.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?